The evolution of progesterone receptor ligands

Medicinal Research Reviews

Volumn 27, Issue 3, 2007, Pages 374-400

  Madauss, Kevin P ^a   Stewart, Eugene L ^a   Williams, Shawn P ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Nuclear receptor; Progesterone; Progesterone receptor; Steroid receptor

Indexed keywords

CELL NUCLEUS RECEPTOR; CHLORMADINONE; DESOGESTREL; DIENOGEST; DROSPERINONE; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; LEVONORGESTREL; LIGAND; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL; MESTRANOL; MESTRANOL PLUS NORETHISTERONE; MESTRANOL PLUS NORETYNODREL; MIFEPRISTONE; NANDROLONE; NORETHISTERONE; NORETYNODREL; NORGESTIMATE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR; SPIRONOLACTONE; STEROID RECEPTOR; TESTOSTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST TENDERNESS; DRUG ACTIVITY; DRUG EFFECT; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; HYPERTENSION; LIBIDO DISORDER; MOOD CHANGE; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; WEIGHT GAIN;

CONTRACEPTIVES, ORAL; FURANS; HUMANS; INDOLES; LIGANDS; MODELS, MOLECULAR; OXAZINES; PROGESTINS; QUINOLINES; RECEPTORS, PROGESTERONE; STEROIDS;

EID: 34247612009     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20083     Document Type: Review

References (103)

1. Critchley HOD, Kelly RW, Brenner RM, Baird DT. Antiprogestins as a model for progesterone withdrawal. Steroids 2003;68:1061-1068.
2. Stanczyk FZ, Henzl MR. Use of the name "Progestin". Contraception 2001;64:1-2.
3. Carson-Jurica MA, Lee AT, Dobson AW, Conneely OM, Schrader WT, O'Malley BW. Interaction of the chicken progesterone receptor with heat shock protein (HSP) 90. J Steroid Biochem 1989;34:1-9.
4. Kost SL, Smith DF, Sullivan WP, Welch WJ, Toft DO. Binding of heat shock proteins to the avian progesterone receptor. Mol Cell Biol 1989;9:3829-3838.
5. Schowalter DB, Sullivan WP, Maihle NJ, Dobson AD, Conneely OM, O'Malley BW, Toft DO. Characterization of progesterone receptor binding to the 90- and 70-kDa heat shock proteins. J Biol Chem 1991;266:21165-21173.
6. Smith DF. Dynamics of heat shock protein 90-progesterone receptor binding and the disactivation loop model for steroid receptor complexes. Mol Endocrinol 1993;7:1418-1429.
7. Edwards D, DeMarzo A, Onate S, Beck C, Estes P, Nordeen S. Mechanisms controlling steroid receptor binding to specific DNA sequences. Steroids 1991;56:271-278.
8. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995;270:1354-1357.
9. Smith CL, Onate SA, Tsai MJ, O'Malley BW. CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc Natl Acad Sci USA 1996;93:8884-8888.
10. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 1997;11:693-705.
11. Fraenkel L. Die Funktion des Corpus luteum. Archive fur Gynaekologia 1903;68:438-535.
12. Herrman E, Stein M. Über die Wirkung eines Hormones des Corpus luteum auf männliche und weibliche Keimdrüsen. Wien Klin Wochenschr 1916;29:778-782.
13. Allen WM, Corner GW. Physiology of the Corpus luteum-II. Production of a special uterine reaction (progestational proliferation) by extracts of the corpus luteum. Am J Physiol 1929;88:340-346.
14. Corner GW, Allen WM. Physiology of the corpus luteum. Am J Physiol 1929;88:326-339.
15. Clauberg CW. Zur Physiologie und Pathologie de Sexualhormone, im Besonderen des Hormoins des Corpus luteum. I. Der biologische test für das Luteumhormon (das spezielle Hormon des Corpus luteum) am infantilen Kaninchen. Zentralblatt für Gynäkologie 1930;54:2727-2770.
16. Butenandt A, Westphal O. Zur Isolierung und Charakterisierung des Corpus-luteum-Hormones. Ber Deutsch Chem Gesellsch 1934;67:1440-1442.
17. Harrtman M, Wettstein A. Ein krystallisiertes Hormon aus Corpus luteum. Helv Chim Acta 1934; 17: 878-882.
18. Slotta KH, Ruschig H, Fels E. Reindarstellung der Hormone aus dem Corpus luteum. Ber Deutsch Chem Gesellsch 1934;67:1270-1273.
19. Wintersteiner O, Allen WM. Crystalline progestin. J Biol Chem 1934;107:321-336.
20. Fieser L. In sex hormones. New York, USA: Reinhold; 1949.
21. Fieser L, Fieser M. In steroids. New York, USA: Reinhold; 1959.
22. Butenandt A, Schmidt-Thomé P. Umwandlung des Dehydro-androsterons in 17-iso-Progesteron und Progesteron. Chem Ber 1939;72:1112-1118.
23. Plattner PA, Heuser H, Segre A. Syntheses des 14-Allo-17-iso- progesterones. Helv Chim Acta 1948;31:249-256.
24. Haberlandt L. Über hormonale Sterilisierung des weiblichen Tierkörpers. En Beitag zur Lehre von der inneren Sekretion des Eierstockes und der Plazenta. Wein and Berlin, Germany: Urban & Schwarzenberg; 1924.
25. Pincus G. Some effects of progesterone and related compounds upon reproductoin and early development in mammals. Acta Endocr Copenh Suppl 1956;28:18-36.
26. Ehrenstein M. Investigation on steroids-VIII. Lower homologs of hormones of the pregnane series: 10-Nor-11-desoxycorticosterone acetate and 10-nor-progesterone. J Org Chem 1944;9:435-456.
27. Allen WM, Ehrenstein M. 10-Nor-progesterone. A physiologically active lower homolog of progesterone. Science 1944;100:251-252.
28. Birch AJ. Hydroaromatic steroid hormones-I. 10-Nortestosterone. J Chem Soc 1950;1:367-368.
29. Johnson AW, Rydon HN, de la Mare PBD, Birch AJ, Baddiley J, Falk JE, Rimington C. Organic chemistry. Ann Rept Progr Chem Chem Soc London 1950;47:126-284.
30. Miramontes L, Rosenkranz G, Djerassi C. The synthesis of 19-norprogesterone. J Am Chem Soc 1951;73:3540-3542.
31. Tullner WW, Hertz R. High progestational activity of 19-norprogesterone. J Clin End Met 1952;12:916-922.
32. Inhoffen HH, Logemann W, Hohlweg W, Serini A. Untersuchunger in der seaxualhormon-Reihe. Chem Ber 1938;71:1024-1032.
33. 4-3-ketosteroids and a new partial synthesis of the natural estrogens. J Am Chem Soc 1950;72:4534-4540.
34. Djerassi C, Miramontes L, Rosenkranz G, Sondheimer F. Steroids. LIV Synthesis of 19-Nor-17α-ethynyltestosterone and 19-Nor-17α- methyltestosterone. J Am Chem Soc 1954;76:4092-4094.
35. Colton FB. 13-methyl-17-ethynyl-17-hydroxy-1,2,3,4,6,7,8,9,11,12,13,14, 16,17-tetradecahydro-15H-cyclopenta(a)phenanthren-3-one and its preparation. USA Patent 2725389 1955.
36. Hertz R, Tullner WW, Raffelt E. Progestational activity of orally administered 17 alpha-ethinyl-19-nortestosterone. Endocrinology 1954;54:228-230.
37. Slechta RF, Chang MC, Pincus G. Effects of progesterone and related compounds on mating and fertility in the rat. Fertil Steril 1954;5:282-293.
38. Tyler ET. Comparative evaluation of various types of administration of progesterone. J Clin Endocrinol Metab 1955;15:881-886.
39. Garcia CR, Pincus G, Rock J. Effects of three 19-nor steroids on human ovulation and menstruation. Am J Obstet Gynecol 1958;75:82-97.
40. Rock J, Pincus G, Garcia CR. Effects of certain 19-nor-steroids on the normal human menstral cycle. Science 1956;124:891-893.
41. Rock J, Garcia CR, Pincus G. Synthetic progestins in the normal human menstral cycle. Recent Prog Horm Res 1957;13:323-346.
42. Rice-Wray E. Field study of Enovid as a contraceptive agent. Chicago, USA: Searle Research Labs; 1957. pp 78-85.
43. Colton FB. Steroids and "the pill": Early steroid research at Searle. Steroids 1992;57:624-630.
44. Djerassi C. Steroid oral contraceptives. Science 1966;151:1055-1061.
45. Djerassi C. Steroid research at Syntex: "The pill" and cortisone. Steroids 1992;57:631-641.
46. Kulier R, Helmerhost FM, Maitra N, Gulmezoglu AM. Effectiveness and acceptability of progestogens in combined oral contraceptives - a systematic review. Reprod Health 2004;1:1-1.
47. Krattenmacher R. Drospirenone: Pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38.
48. Sirtruk-Ware R. New Progestogens a review of their effects in Perimenopausal and Postmenopausal women. Drugs Aging 2004;21:865-883.
49. Bledsoe RK, Madauss KP, Holt JA, Apolito CJ, Lambert MH, Pearce KH, Stanley TB, Stewart EL, Trump RP, Willson TM, Williams SP. A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor. J Biol Chem 2005;280:31283-31293.
50. Agarwal MK, Mirshahi M. General overview of mineralocorticoid hormone action. Pharmacol Ther 1999;84:273-326.
51. Rogerson FM, Fuller PJ. Mineralocorticoid action. Steroids 2000;65:61-73.
52. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FT, Sigler PB, Lifton RP. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000;289:119-123.
53. Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A. Conception and pharmacodynamic profile of drosperinone. Steroids 2003;68:891-905.
54. Baulieu E-E. Contragestion and other clinical applications of RU486, an antiprogesterone at the receptor. Science 1989;245:1351-1357.
55. Sirtruk-Ware R, Spitz IM. Pharmacological properties of mifepristone: Toxicology and safety in animal and human studies. Contraception 2003;68:409-420.
56. Robbins A, Spitz IM. Mifepristone: Clinical pharmocology. Clin Obst Gyn 1996;39:436-450.
57. Cremmins MD. Medical abortion regimens: Historical context and overview. Am J Obstet Gynecol 2000;183:3-9.
58. Chwalisz K, Demanno D, Garg R, Larsen L, Mattia-Goldberg C, Stickler T. Theraputic potential for the selective progesterone receptor modulator, asoprisnil in the treatment of leiomyomata. Sem Reprod Med 2004;22:113-119.
59. Chwalisz K, Elger W, Stickler T, Mattia-Goldberg C, Larsen L. The effect of 1-month administration of Asoprisnil(J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod 2005;20:1090-1099.
60. Demanno D, Elger W, Garg R, Lee R, Schneider B, Hess-Stump H, Schubert G, Chwalisz K. Aoprisnil (J867): A selective progesterone receptor modulator for gynecological therapy. Steroids 2003;68:1019-1032.
61. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in treatment of leiomyomata and endometriosis. Endocr Rev 2005;26:423-438.
62. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: Mechanisms of action and clinical applications. Hum Reprod Update 2005;11:293-307.
63. Winneker RC, Fensome A, Wrobel JE, Zhang Z, Zhang P. Nonsteroidal progesterone receptor modulator: Structure activity relationships. Sem Reprod Med 2005;23:46-57.
64. Zhang P, Fensome A, Wrobel J, Winneker RC, Zhang Z. Nonsteroidal progesterone receptor modulators. Expert Opin Ther Pat 2003;13:1839-1847.
65. Zhi L, Tegley CM, Pio B, West SJ, Marschke KB, Mais DE, Jones TK. Nonsteroidal progesterone receptor antagonists based on 6- thiophenylhydroquinolines. Bioorg Med Chem Lett 2000;10:415-418.
66. Zhang P, Terefenko EA, Fensome A, Zhang Z, Zhu Y, Cohen J, Winneker RC, Wrobel J, Yardley J. Potent nonsteroidal progesterone receptor agonists: Synthesis and SAR study of 6-aryl benzoxazines. Bioorg Med Chem Lett 2002;12:787-790.
67. Zhang Z, Lundeen SG, Zhu Y, Carver JM, Winneker RC. In vitro characterization of trimegestone: A new potent and selective progestin. Steroids 2000;65:637-643.
68. Beck CA, Weigel NL, Moyer ML, Nordeen SK, Edwards DP. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc Natl Acad Sci USA 1993;90:4441-4445.
69. Zhang Z, Funk C, Glasser SR, Mulholland J. Progesterone regulation of heparin-binding epidermal growth factor-like growth factor gene expression during sensitization and decidualization in the rat uterus: Effects of the antiprogestin, ZK 98.299. Endocrinology 1994;135:1256-1263.
70. Zhang P, Terefenko EA, Fensome A, Wrobel J, Winneker RC, Zhang Z. Novel 6-aryl-1,4-dihydrobenzo[d]oxazine-2-thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists. Bioorg Med Chem Lett 2003;13:1313-1316.
71. Fensome A, Koko M, Wrobel J, Zhang P, Zhang Z, Cohen J, Lundeen S, Rudnick K, Zhu Y, Winneker RC. Novel 5-aryl-1,3-dihydro-indole-2-thiones: Potent, orally active progesterone receptor agonists. Bioorg Med Chem Lett 2003;13:1317-1320.
72. Collins MA, Hudak V, Bender R, Fensome A, Zhang P, Miller L, Winneker RC, Zhang Z, Zhu Y, Cohen J, Unwalla RJ, Wrobel J. Novel pyrrole-containing progesterone receptor modulators. Bioorg Med Chem Lett 2004;14:2185-2189.
73. Fensome A, Chopra R, Cohen J, Collins MA, Hudak V, Malakian K, Olland A, Svenson K, Terefenko EA, Unwalla RJ, Wilhelm JM, Wolfrom S, Zhu Y, Zhang Z, Zhang P, Winneker RC, Wrobel J. Synthesis and SAR of novel, 6-aryl-1,4- dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading to the potent and selective non-steroidal PR agonist Tanaproget. 228th American Chemical Society National Meeting, Philadelphia, PA. 2004.
74. Zhang Z, Olland AM, Zhu Y, Cohen J, Berrodin T, Chippari S, Appavu C, Li S, Wilhelm J, Chopra R, Fensome A, Zhang P, Wrobel J, Unwalla RJ, Lyttle CR, Winneker RC. Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget. J Biol Chem 2005;280:28468-28475.
75. Zhi L, Tegley CM, Pio B, Edwards JP, Motamedi M, Jones TK, Marschke KB, Mais DE, Risek B, Schrader WT. Benzylidene-1,2-dihydrochromeno[3,4-f] quinolines as selective progesterone receptor modulators. J Med Chem 2003;46:4104-4112.
76. Edwards J, Zhi L, Pooley C, Tegley C, West S, Wang M, Gottardis M, Pathirana C, Schrader W, Jones T. Preparation, resolution, and biological evaluation of 5-aryl-1, 2-dihydro-5H-chromeno[3,4-f]quinolines: Potent, orally active, nonsteroidal progesterone receptor agonists. J Med Chem 1998;41:2779-2785.
77. Zhi L, Tegley CM, Edwards JP, West SJ, Marschke KB, Gottardis MM, Mais DE, Jones TK. Alkyl-1,2-dihydrochromeno[3,4-f]quinolines: A novel class of nonsteroidal progesterone receptor modulators. Bioorg Med Chem Lett 1998;8:3365-3370.
78. Zhi L, Tegley CM, Pio B, Edwards JP, Jones TK, Marschke KB, Mais DE, Risek B, Schrader WT. Synthesis and biological activity of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives as progester-one receptor modulators. Bioorg Med Chem Lett 2003;13:2071-2074.
79. Palmer S, Campen CA, Allan GF, Rybczynski P, Haynes-Johnson D, Hutchins A, Kraft P, Kiddoe M, Lai M-T, Lombardi E, Pedersen P, Hodgen G, Combs DW. Nonsteroidal progesterone receptor ligands with unprecedented receptor selectivity. J Steroid Biochem Mol Biol 2000;75:33-34.
80. McPhail MK. The assay of progestin. J Physiol London 1934;83:145-156.
81. Tabata Y, Miike N, Hatsu M, Kurata Y, Yaguchi T, Someya A, Miyadoh S, Hoshiko S, Tsuruoka T, Omoto S. PF1092A, B and C, new nonsteroidal progesterone receptor ligands produced by Penicillium oblatum. I. Taxonomy of producing strain, fermentation, isolation and biological activities. J Antibiotics 1997;50:304-308.
82. Tabata Y, Iizuka Y, Shinei R, Kurihara K, Okonogi T, Hoshiko S, Kurata Y, Hoshiko S. CP8668, a novel orally active nonsteroidal progesterone receptor modulator with tetrahydrobenzindolone skeleton. Eur J of Pharm 2003;461:73-78.
83. Dong Y, Roberge JY, Wang Z, Wang X, Tamasi J, Dell V, Golia R, Corte JR, Liu Y, Fang T, Anthony MN, Schnur DM, Agler ML, Dickson JK, Jr., Lawrence RM, Prack MM, Seethala R, Feyen JHM. Characterization of a new class of selective nonsteroidal progesterone receptor agonists. Steroids 2004;69:201-217.
84. Pooley C, Edwards J, Goldman M, Wang M, Marschke K, Crombie D, Jones T. Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore. J Med Chem 1998;41:3461-3466.
85. Zhi L, Ringgenberg JD, Edwards JP, Tegley CM, West SJ, Pio B, Motamedi M, Jones TK, Marschke KB, Mais DE, Schrader WT. Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore. Bioorg Med Chem Lett 2003;13:2075-2078.
86. Hamann LG, Winn DT, Pooley CLF, Tegley CM, West SJ, Farmer LJ, Zhi L, Edwards JP, Marschke KB, Mais DE, Goldman ME, Jones TK. Nonsteroidal progesterone receptor antagonists based on a conformationally- restrictedsubseries of 6-aryl-1,2-dihydro-2,2,4-trimethylquinolines. Bioorg Med Chem Lett 1998;8:2731-2736.
87. Zhang P, Terefenko EA, Wrobel J, Zhang Z, Zhu Y, Cohen J, Marschke KB, Mais D. Synthesis and progesterone receptor antagonist activities of 6-aryl benzimidazolones and benzothiazolones. Bioorg Med Chem Lett 2001;11:2747-2750.
88. Fensome A, Bender R, Cohen J, Collins MA, Mackner VA, Miller LL, Ullrich JW, Winneker RC, Wrobel J, Zhang P, Zhang Z, Zhu Y. New progesterone receptor antagonists: 3,3-disubstituted-5-aryloxindoles. Bioorg Med Chem Lett 2002;12:3487-3490.
89. Zhang P, Terefenko EA, Fensome A, Wrobel J, Winneker RC, Lundeen S, Marschke KB, Zhang Z. Aryl-1,4-dihydrobenzo[d][1,3]oxazin-2-ones: A novel class of potent, selective, and orally active nonsteroidal progesterone receptor antagonists. J Med Chem 2002;45:4379-4382.
90. Bullock WH, Kluender HCE, Collibee WL, Dally R, Rodriguez ME, Wang M. Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents. WO0220526 2002.
91. Dixon BR, Bagi CM, Brennan CR, Brittelli D, Bullock WH, Chen J, Collibee WL, Dally R, Johnson JS, Kluender HCE, Lathrop WF, Liu P, Mase CA, Redma AM, Scott WJ, Urbahns K, Wolanin DJ. Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents. US6353006 2002.
92. Jones DG, Liang X, Stewart EL, Noe RA, Kaliander LS, Madauss KP, Williams SP, Thompson SK, Gray DW, Hoekstra WJ. Discovery of non-steroidal mifepristone mimetics: Pyrazoline-based PR antagonists. Bioorg Med Chem Lett 2005;15:3203-3206.
93. Madauss KP, Deng SJ, Austin RJH, Lambert MH, McLay I, Pritchard J, Short SA, Stewart EL, Uings IJ, Williams SP. Progesterone receptor ligand binding pocket flexibility: Crystal structures of norethindrone and mometasone furoate complexes. J Med Chem 2004;47:3381-3387.
94. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, Otto N, Joschko S, Scholz P, Wegg A, Basler S, Schafer M, Egner U, Carrondo MA. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 2000;275:26164-26171.
95. Williams SP, Sigler PB. Atomic structure of progesterone complexed with its receptor. Nature 1998;393:392-396.
96. Zhang Z, Olland AM, Zhu Y, Cohen J, Berrodin T, Chippari S, Appavu C, Li S, Wilhem J, Chopra R, Fensome A, Zhang P, Wrobel J, Unwalla RJ, Lyttle CR, Winneker RC. Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget. J Biol Chem 2005;280:28468-28475.
97. Allan GF, Leng X, Tsai SY, Weigel NL, Edwards DP, Tsai MJ, O'Malley BW. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem 1992;267:19513-19520.
98. Allan GF, Lombardi E, Haynes-JohnsonD, Palmer S, Kiddoe M, Kraft P, Campen C, Rybczynski P, Combs DW, Phillips A. Induction of a novel conformation in the progesterone receptor by ZK299 involves a defined region of the carboxyl-terminal tail. Mol Endocrinol 1996;10:1206-1213.
99. Kauppi B, Jakob C, Färnegårdh M, Yang J, Ahola H, Alarcon M, Calles K, Engström O, Harlan J, Muchmore S, Ramqvist A-K, Thorell S, Öhman L, Greer J, Gustafsson J-Å, Carlstedt-Duke J, Carlquist M. The 3D-structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain; RU-486 induces a transconformation that leads to active antagonism. J Biol Chem 2003;278:22748-22754.
100. Zhang X, Jeyakumar M, Petukhov S, Bagchi MK. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol Endocrinol 1998;12:513-524.
101. Vegeto E, Allan GF, Schrader WT, Tsai MJ, McDonnell DP, O'Malley BW. The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 1992;69:703-713.
102. Xu J, Nawaz Z, Tsai SY, Tsai MJ, O'Malley BW. The extreme C terminus of progesterone receptor contains a transcriptional repressor domain that functions through a putative corepressor. Proc Natl Acad Sci USA 1996;93:12195-12199.
103. Benhamou B, Garcia T, Lerouge T, Vergezac A, Gofflo D, Bigogne C, Chambon P, Gronemeyer H. A single amino acid that determines the sensitivity of progesterone receptors to RU486. Science 1992;255:206-209.